Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.180
-0.010 (-0.84%)
At close: Nov 14, 2025, 4:00 PM EST
1.187
+0.007 (0.62%)
After-hours: Nov 14, 2025, 7:55 PM EST
Allarity Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
17.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALLR News
- 20 hours ago - Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - GlobeNewsWire
- 2 months ago - Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer - GlobeNewsWire
- 5 months ago - Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer - GlobeNewsWire